Heart Failure Clinical Trials in Dallas, Texas
30 studies are recruiting for heart failure in Dallas, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, and with at least one additional risk factor for HF. The study will include an optional pre-screenin…
- Stage
- Phase 3
- Ages
- 40 and older
- Site
- Research Site, Dallas, Texas
- Locations
- 957 in total
- Run by
- AstraZeneca
-
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Dallas, TX Investigative Site 10042, Dallas, Texas
- Locations
- 356 in total
- Run by
- Colorado Prevention Center
-
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
The goal of this study is to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 Left Ventricular Assist System when used for the treatment of advanced, refractory, left ventricular heart failure.
- Stage
- Not phased
- Ages
- 18 to 100
- Site
- Baylor University Medical Center, part of Baylor Scott & White Health, Dallas, Texas
- Locations
- 47 in total
- Run by
- BrioHealth Solutions, Inc.
-
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
This study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF) of less than 40%. People can join the study if they have been diagnosed with chronic HF at least 3 months before they start on the study. The purpose of this study is to find ou…
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Texas Health Research and Education Institute, Dallas, Texas
- Locations
- 588 in total
- Run by
- Boehringer Ingelheim
-
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
This study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16 of the Base Period. The primary hypothesis is that vericiguat is superior to placebo in reducing NT-proBNP at Week 16 of the Base Period.
- Stage
- Phase 2
- Ages
- 0 to 17
- Site
- Children's Health-The Heart Center ( Site 0015), Dallas, Texas
- Locations
- 109 in total
- Run by
- Merck Sharp & Dohme LLC
-
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.
- Stage
- Phase 3
- Ages
- 18 to 85
- Site
- Baylor University Medical Center, Dallas, Texas
- Locations
- 205 in total
- Run by
- Cytokinetics
-
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK…
- Stage
- Not phased
- Ages
- 0 to 20
- Site
- University of Texas-Southwestern Medical Center Dallas, Dallas, Texas
- Locations
- 52 in total
- Run by
- Duke University
-
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empa…
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Texas Health Research and Education Institute, Dallas, Texas
- Locations
- 652 in total
- Run by
- Boehringer Ingelheim
-
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.
- Stage
- Not phased
- Ages
- Any age
- Site
- Research site, Dallas, Texas
- Locations
- 333 in total
- Run by
- Medtronic
-
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to f…
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Renal Disease Research Institute, Dallas, Texas
- Locations
- 838 in total
- Run by
- Novo Nordisk A/S
-
Alleviant ALLAY-HF Study
Prospective, multicenter, randomized, sham-controlled, double blinded, adaptive study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with HFpEF/HFmrEF.
- Stage
- Not phased
- Ages
- 40 and older
- Site
- UT Southwestern, Dallas, Texas
- Locations
- 93 in total
- Run by
- Alleviant Medical, Inc.
-
CSP #2025 - Geriatric OUt-of-hospital Randomized MEal Trial in Heart Failure: Veterans Affairs (GOURMET-VA)
The purpose of this multi-center clinical trial is to study the efficacy and safety of providing nutritional support added to the study-defined standard of care which consists of standardized dietary education and a single dietary counseling session shortly after discharge, versus study-defined sta…
- Stage
- Not phased
- Ages
- 60 and older
- Site
- VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas, Texas
- Locations
- 16 in total
- Run by
- VA Office of Research and Development
-
Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System
There are two primary goals of this multicenter clinical trial that combines an FDA device trial and a phase II drug trial in the same study cohort. These two goals are to: 1. To evaluate the safety and effectiveness of the Cardiohelp Device for VA-ECMO (heart-lung support) for up to 30 days of sup…
- Stage
- Phase 2
- Ages
- 0 to 16
- Site
- Children's Health Dallas, Dallas, Texas
- Locations
- 5 in total
- Run by
- Stanford University
-
Assessment of CCM in HF With Higher Ejection Fraction
The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.
- Stage
- Not phased
- Ages
- 18 and older
- Site
- Baylor Scott and White Research Institute, Dallas, Texas
- Locations
- 105 in total
- Run by
- Impulse Dynamics
-
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by cha…
- Stage
- Phase 2
- Ages
- 40 to 84
- Site
- University of Texas Southwestern Medical Center, Dallas, Texas
- Locations
- 117 in total
- Run by
- Novo Nordisk A/S
-
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
This is a prospective, multi-center, open label, randomized control clinical trial evaluating the safety and efficacy of the Cordella™ Pulmonary Artery Sensor System in NYHA Class II-III Heart Failure Patients (PROACTIVE-HF-2 Trial). The study contains of 5 arms: NYHA II Cohort - To demonstrate saf…
- Stage
- Not phased
- Ages
- 18 and older
- Site
- Medical City Healthcare Dallas, Dallas, Texas
- Locations
- 48 in total
- Run by
- Endotronix, Inc.
-
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.
- Stage
- Not phased
- Ages
- 18 and older
- Site
- Baylor University Hospital, Dallas, Texas
- Locations
- 68 in total
- Run by
- Abbott Medical Devices
-
Home-based Cardiac Rehabilitation in Heart Failure
This study evaluates a mobile health (mHealth) home-based cardiac rehabilitation program for patients with heart failure. We will stratify randomization between rural and urban populations, with the goal to assess implementation of cardiac rehabilitation across these two geographic areas. . The stu…
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- University of Texas Southwestern Medical Center, Dallas, Texas
- Locations
- 2 in total
- Run by
- University of Texas Southwestern Medical Center
-
IEEM-Heat and Heart Failure
We will test the hypothesis that increasing skin wetness, and thus evaporative cooling, will attenuate the increase in core body temperature and accompanying cardiac stress during heat wave conditions in individuals with congestive heart failure. Secondly, we propose that wearing a water-saturated …
- Stage
- Not phased
- Ages
- 45 and older
- Site
- Institute for Exercise and Environmental Medicine - Texas Health Presbyterian Hospital Dallas, Dallas, Texas
- Run by
- University of Texas Southwestern Medical Center
-
Using Ultromics EchoGo HFpEF Algorithm to Identify and Treat High Heart Failure Risk in Patients With Type 2 Diabetes
A pragmatic electronic health record (EHR) based randomized controlled trial to evaluate the utility of providing Ultromics EchoGo analysis results and recommendations for HF risk prevention therapies using an EHR embedded clinical decision support tool.
- Stage
- Not phased
- Ages
- Any age
- Site
- UT Southwestern Medical Center, Dallas, Texas
- Run by
- University of Texas Southwestern Medical Center
-
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Whether these drugs have similar effects in patients with type 1 diabetes (T1D) remains unknown because …
- Stage
- Phase 3
- Ages
- 18 to 75
- Site
- University of Texas Southwestern, Dallas, Texas
- Locations
- 19 in total
- Run by
- Alessandro Doria
-
XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)
The purpose of this study is to evaluate if Non-Ischemic Heart Preservation (NIHP) of extended criteria donor hearts using the XVIVO Heart Preservation System (XHPS) is a safe and effective way to preserve and transport hearts for transplantation.
- Stage
- Not phased
- Ages
- 18 and older
- Site
- University of Texas Southwestern Medical Center, Dallas, Texas
- Locations
- 14 in total
- Run by
- XVIVO Perfusion
-
Efficacy of LoDoCo in Improving Exercise Capacity Among Patients With HFpEF and Inflammation
The purpose of this research study is to determine the effectiveness of low dose colchicine (LoDoCo) on measures of exercise capacity, physical function, frailty, and quality of life, among patients with heart failure with chronic stable preserved ejection fraction (HFpEF) and systemic inflammation…
- Stage
- Phase 2
- Ages
- 50 and older
- Site
- UT Southwestern Medical Center, Dallas, Texas
- Run by
- University of Texas Southwestern Medical Center
-
NT-ProBNP-based Heart Failure Screening and Prevention Trial in Patients With Type 2 Diabetes: STRONG-DM Study
A pragmatic, randomized clinical trial to evaluate the effect of a heart failure (HF) risk assessment and prevention strategy incorporating HF clinical risk scores (WATCH-DM) with cardiac biomarker (NT-proBNP) paired with a clinical decision support tool to implement an intensive prevention strateg…
- Stage
- Not phased
- Ages
- Any age
- Site
- University of Texas Southwestern Medical Center, Dallas, Texas
- Run by
- University of Texas Southwestern Medical Center
-
Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients
This phase II, multi-center, open-label study will evaluate the safety and efficacy of utilizing HCV-positive donors for heart transplant in HCV-negative recipients treated with sofosbuvir 400 mg / velpatasvir 100 mg (Epclusa®).
- Stage
- Phase 2
- Ages
- 18 to 90
- Site
- Baylor University Medical Center, Dallas, Texas
- Locations
- 3 in total
- Run by
- Baylor Research Institute
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.